Paving the way for U.S. Market Entry and Global Expansion
PARIS, FRANCE / ACCESS Newswire / May 20, 2025 / Tribun Health, a leader in digital pathology, proudly announces that its flagship web-based image management system, CaloPix®, has received FDA 510(k) clearance for use with two leading whole slide imaging scanners: the Hamamatsu NanoZoomer S360 and the Leica Aperio GT450. This marks the first time a digital pathology software has been cleared with both scanners, representing a major step forward for the U.S. adoption of vendor-agnostic, enterprise-grade solutions.
A pathologist reviews high-resolution whole slide images on CaloPix® at her workstation. The platform's intuitive, web-based interface enables seamless case navigation, diagnostic annotation, and real-time collaboration-empowering clinicians to make
This clearance builds on CaloPix's strong regulatory track record: the solution is CE-marked, Health Canada-approved, and trusted by more than 100 hospitals and laboratories across Europe and Canada. With over 1,000 active users of CaloPix® worldwide, this milestone underscores the platform's scalability, clinical reliability, and rapid adoption across diverse healthcare systems. Now, with FDA clearance secured, Tribun Health is ready to bring its proven enterprise solution to hospitals and labs across the United States.
Besides these regulatory achievements, CaloPix® has also been recognized three times as "Best in KLAS" for digital pathology, a global benchmark for excellence in healthcare IT. This prestigious recognition highlights Tribun Health's commitment to customer satisfaction, operational excellence, and product innovation.
"This is a major commercial and clinical milestone for us," said Jean-François Pomerol, CEO of Tribun Health. "We're entering the U.S. with a solution that has already proven its value in demanding, high-throughput clinical environments. With CaloPix®, we offer a platform trusted by top-tier institutions, awarded Best in KLAS multiple times -and now validated by the FDA. As the market accelerates toward widespread clinical adoption, we're thrilled to expand our reach and solidify our position as a truly global player."
Built for Enterprise, Designed for Performance, Ready for Cloud
CaloPix® goes far beyond a traditional image viewer-it's a powerful, all-in-one digital pathology platform tailored for the needs of modern healthcare systems, large hospital networks, and academic institutions.
Key capabilities include:
Web-based, Cloud ready, zero-footprint architecture-no local installation required
High-throughput case management and diagnostic reporting to streamline daily workflows
Seamless integration with LIS and VNA systems for unified data access across the enterprise
Built-in telepathology and remote collaboration tools for second opinions and network-wide consultations
Archiving, export, and quality control features to support regulatory compliance and research initiatives
Meeting the Moment: Solving U.S. Market Challenges
The U.S. faces a growing mismatch between rising pathology case volumes and a shrinking workforce. At the same time, there is a clear push for multi-site collaboration, integrated diagnostics, and precision medicine initiatives.
With this FDA clearance, CaloPix® empowers U.S. hospitals and labs to:
Digitize pathology workflows at scale
Reduce turnaround times and improve reporting accuracy
Collaborate remotely across institutions
Prepare for AI adoption with structured, interoperable data
Building on our success with public health networks, cancer centers, academic hospitals and private laboratory groups across Europe and Canada, we are now ready to scale in the world's largest healthcare market-the United States.
* CaloPix® is CE mark, HC cleared, FDA cleared. Please refer to IFU for intended use.
About Tribun Health
Tribun Health is a global leader in digital pathology, offering award-winning solutions that improve workflow efficiency, diagnostic accuracy, and patient outcomes. We assist hospitals and laboratories in transitioning from glass slide pathology to fully digital solutions, leveraging AI and data-driven technology to enhance precision and reduce turnaround times. Our mission is simple: to ensure every cancer patient receives a timely and informed diagnosis-because every moment counts. By advancing pathology with cutting-edge innovations, we are shaping the future of cancer care. For more information, visit Tribun Health and follow us on LinkedIn and X.
Contact Information
Andreia Beyer
VP, Global Marketing & Managing Director, North America
abeyer@tribun.health
+1 (416) 565-0474
SOURCE: Tribun Health
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tribun-health-achieves-fda-clearance-for-calopix-digital-pathology-pl-1028836
